Andreas Varkaris
Assistant Professor in Medicine Harvard Medical School
Seminars
Wednesday 9th September 2026
Is Perfect Selectivity Necessary? Rethinking KRAS Targeting in the Era of Resistance
1:00 pm
- Comparing mutant-selective versus isoform-selective KRAS inhibitors to evaluate trade-offs between biochemical precision and clinical durability
- Exploring how partial selectivity may extend duration of response and delay resistance in preclinical and clinical models
- Integrating frontline patient data to inform design of next-generation KRAS-targeted therapies that balance efficacy, safety, and real-world performance
